MedTrace Logo

Can a Nasal Decongestant Test Predict Treatment Outcomes in Seasonal Allergic Rhinitis?

NCT00618332 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 40

Last updated 2014-02-14

Study results available
· View outcomes & findings →

Summary

We hypothesize that those patients with purely seasonal allergic rhinitis will decongest better than those subjects with another cause contributing to their symptoms. These latter patients will not improve as well on an intranasal steroid as those who decongest well, potentially explaining the 60% response rate in prior studies.

Conditions

  • Seasonal Allergic Rhinitis

Interventions

DRUG

mometasone furoate nasal spray

2 puffs in each nostril once a day for 2 weeks

DRUG

placebo

2 puffs in each nostril once a day for 2 weeks

Sponsors & Collaborators

  • Schering-Plough

    collaborator INDUSTRY

  • University of Chicago

    lead OTHER

Principal Investigators

  • Robert M Naclerio, MD · University of Chicago

Study Design

Allocation
RANDOMIZED
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
60 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-04-30
Primary Completion
2008-07-31
Completion
2010-07-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00618332 on ClinicalTrials.gov